Expression of cdc25B and cdc25A in medullary thyroid carcinoma: cdc25B expression level predicts a poor prognosis.

Abstract

Cdc25B and cdc25A phosphatases are prominent stimulators of cell cycle progression and have been suggested to play oncogenic roles. In this study, we immunohistochemically investigated the expression of these phosphatases in medullary thyroid carcinoma. Cdc25B was positive in 35.8% of cases examined. Its positivity was linked only to patient age. However, patients with cdc25B-positive tumors showed a significantly worse disease-free survival rate (P=0.0210) than those with cdc25B-negative tumors. Cdc25A was positive in only 17.2% of cases and was not related to clinicopathological parameters or prognosis. These findings suggest that cdc25B can be regarded as having prognostic significance and as a novel marker of biologically aggressive characteristics in this carcinoma.

• Authors: Yasuhiro Ito, Hiroshi Yoshida, Chisato Tomoda, Takashi Uruno, Yuuki Takamura, Akihiro Miya, Kaoru Kobayashi, Fumio Matsuzuka, Kanji Kuma, Yasushi Nakamura, Kennichi Kakudo, Akira Miyauchi
• Journal: Cancer letters (Cancer Lett) Vol. 229 Issue 2 Pg. 291-7 (Nov 18 2005) ISSN: 0304-3835 [Print] Ireland
• PMID: 16095809 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Cell Cycle Proteins
• CDC25A protein, human
• CDC25B protein, human
• cdc25 Phosphatases

Topics

• Adolescent
• Adult
• Age Factors
• Aged
• Biomarkers, Tumor (analysis)
• Carcinoma, Medullary (metabolism, mortality, pathology)
• Cell Cycle Proteins (biosynthesis)
• Disease-Free Survival
• Female
• Humans
• Immunohistochemistry
• Male
• Middle Aged
• Prognosis
• Thyroid Neoplasms (metabolism, mortality, pathology)
• cdc25 Phosphatases (biosynthesis)